KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBIT (2018 - 2025)

Castle Biosciences' EBIT history spans 7 years, with the latest figure at -$3.8 million for Q4 2025.

  • For Q4 2025, EBIT fell 194.49% year-over-year to -$3.8 million; the TTM value through Dec 2025 reached -$42.8 million, down 593.77%, while the annual FY2025 figure was -$42.8 million, 593.77% down from the prior year.
  • EBIT for Q4 2025 was -$3.8 million at Castle Biosciences, up from -$6.8 million in the prior quarter.
  • Across five years, EBIT topped out at $5.1 million in Q3 2024 and bottomed at -$31.5 million in Q1 2023.
  • The 5-year median for EBIT is -$7.8 million (2021), against an average of -$10.8 million.
  • The largest annual shift saw EBIT crashed 1265.89% in 2021 before it skyrocketed 171.58% in 2024.
  • A 5-year view of EBIT shows it stood at -$15.2 million in 2021, then plummeted by 50.5% to -$22.8 million in 2022, then soared by 75.22% to -$5.7 million in 2023, then soared by 171.58% to $4.0 million in 2024, then crashed by 194.49% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's EBIT are -$3.8 million (Q4 2025), -$6.8 million (Q3 2025), and -$4.3 million (Q2 2025).